TY - JOUR
T1 - Interim 2017/18 influenza seasonal vaccine effectiveness
T2 - Combined results from five European studies
AU - I-MOVE/I-MOVE+ group
AU - Rondy, Marc
AU - Kissling, Esther
AU - Emborg, Hanne Dorthe
AU - Gherasim, Alin
AU - Pebody, Richard
AU - Trebbien, Ramona
AU - Pozo, Francisco
AU - Larrauri, Amparo
AU - McMenamin, Jim
AU - Valenciano, Marta
AU - Kaic, Bernard
AU - Filipovic, Sanja Kurecic
AU - Visekruna-Vucina, Vesna
AU - Novosel, Iva Pem
AU - Lovric, Zvjezdana
AU - Petrović, Goranka
AU - Krause, Tyra Grove
AU - Fische, Thea Kølsen
AU - Lina, Bruno
AU - Falchi, Alessandra
AU - Vilcu, Ana Maria
AU - Souty, Cécile
AU - Blanchon, Thierry
AU - van der Werf, Sylvie
AU - Enouf, Vincent
AU - Behillil, Sylvie
AU - Valette, Martine
AU - Bernard-Stoecklin, Sibylle
AU - Lévy-Bruhl, Daniel
AU - Launay, Odile
AU - Loulergue, Pierre
AU - Lenzi, Nezha
AU - Lesieur, Zineb
AU - L’Honneur, Anne Sophie
AU - Galtier, Florence
AU - Agostini, Camille
AU - Serrand, Chris
AU - Merle, Corinne
AU - Foulongne, Vincent
AU - Rizzo, Caterina
AU - Bella, Antonino
AU - Alfonsi, Valeria
AU - Castrucci, Maria Rita
AU - Pagani, Elisabetta
AU - Baldanti, Fausto
AU - Ansaldi, Filippo
AU - Rossolini, Gian Maria
AU - Sanguinetti, Maurizio
AU - Orsi, Andrea
AU - Napoli, Christian
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
AB - Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
UR - http://www.scopus.com/inward/record.url?scp=85043760710&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043760710&partnerID=8YFLogxK
U2 - 10.2807/1560-7917.ES.2018.23.9.18-00086
DO - 10.2807/1560-7917.ES.2018.23.9.18-00086
M3 - Article
AN - SCOPUS:85043760710
VL - 23
JO - Eurosurveillance
JF - Eurosurveillance
SN - 1560-7917
IS - 9
M1 - 18-00086
ER -